S 234821
Alternative Names: S234821Latest Information Update: 05 Dec 2025
At a glance
- Originator Servier
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Sep 2025 Preclinical trials in Solid tumours in France (unspecified route)